MedTrace Logo

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

NCT06807190 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 630

Last updated 2026-04-09

No results posted yet for this study

Summary

The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin Icodec

Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-30
Primary Completion
2027-07-31
Completion
2028-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06807190 on ClinicalTrials.gov